Fig. 6
Combined S63845 and S55746 did not affect normal hematopoietic cell function. a Irradiated NSG mice were transplanted with 105 normal donor CD34 + progenitor cells. Following detectable engraftment in peripheral blood at week 20, mice were treated with (i) S55746 100 mg/kg/d by oral gavage (days 1–5), (ii) S63845 25 mg/kg IV (days 1 and 4), (iii) combination S55746/S63845, or (iv) decitabine 0.4 mg/kg intraperitoneally (days 1–5). Mice were euthanized on day 8 and immunohistological hCD45 + analysis performed on sternal bone marrow and spleen sections captured at ×100 magnification using the Aperio ScanScope. Due to limited availability of donor CD34+cells, 2 mice were engrafted and treated in arms i–iii and one mouse in arm iv; representative images are shown with additional examples in Suppl Fig. 3. b Representative flow cytometric dot plots of flushed femurs from mice treated as indicated in (a) are shown displaying the proportion of marrow cells expressing human versus mouse CD45
